Leerink Partners analyst Whit Mayo reiterated a Buy rating on Alignment Healthcare on July 30 and set a price target of $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whit Mayo has given his Buy rating due to a combination of factors that highlight Alignment Healthcare’s strong performance and promising outlook. The company has demonstrated consistent trends in cost management and clinical differentiation, which are supported by its tech-driven platform. This has resulted in a positive forecast for free cash flow in 2025 and a palpable confidence from management, further bolstered by increased broker engagement and member interaction.
Additionally, Alignment Healthcare’s second-quarter results were robust, with adjusted EBITDA significantly surpassing expectations, partly due to a large sweep payment. The company’s medical loss ratio also improved, indicating effective management of healthcare costs. Looking ahead to 2026, the company anticipates continued top-line growth and margin expansion, with confidence in its ability to navigate industry challenges and improve Star ratings. These factors collectively underscore the rationale behind Mayo’s Buy rating.
According to TipRanks, Mayo is a 2-star analyst with an average return of 0.5% and a 45.28% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, Tenet Healthcare, and Ardent Health Partners, Inc..
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $17.00 price target.